Back to results
US 9,868,723 B2Granted
Mutant-selective EGFR inhibitors and uses thereof
AssigneeCelgene CAR LLC
InventorsKwangho Lee, Deqiang Niu, Matthew Frank Baevsky
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
Claims16
A method of treating a proliferative disorder comprising administering to a patient in need thereof a compound of formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is —CF3 or —Cl;
- W is —O— or —NH—;
- R2 is —R or
- R3 is —R, —C(O)R, or —C(O)OR;
- and
- each R is independently C1-4 alkyl or C1-4 fluoroalkyl;
- and wherein the proliferative disorder is a cancer.
5 more elements
A method of treating a proliferative disorder comprising administering to a patient in need thereof a compound of formula II:
- or a pharmaceutically acceptable salt thereof, wherein:
- R3 is —R, —C(O)R, or —C(O)OR;
- and
- each R is independently C1-4 alkyl or C1-4 fluoroalkyl;
- and
- wherein the proliferative disorder is a cancer.
3 more elements
Dependencies are inferred from the claim text.